22,282 Shares in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Acquired by Intech Investment Management LLC

Intech Investment Management LLC acquired a new stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 22,282 shares of the company’s stock, valued at approximately $429,000.

Several other institutional investors have also modified their holdings of the company. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Syndax Pharmaceuticals during the 2nd quarter worth about $27,000. Values First Advisors Inc. purchased a new stake in shares of Syndax Pharmaceuticals during the 3rd quarter worth approximately $30,000. nVerses Capital LLC purchased a new stake in shares of Syndax Pharmaceuticals during the 2nd quarter worth approximately $33,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Syndax Pharmaceuticals by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company’s stock valued at $58,000 after buying an additional 541 shares in the last quarter. Finally, Quarry LP raised its stake in Syndax Pharmaceuticals by 75.0% during the 2nd quarter. Quarry LP now owns 6,125 shares of the company’s stock worth $126,000 after acquiring an additional 2,625 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. Barclays raised their target price on shares of Syndax Pharmaceuticals from $32.00 to $33.00 and gave the stock an “overweight” rating in a research report on Thursday, August 15th. The Goldman Sachs Group lifted their price objective on shares of Syndax Pharmaceuticals from $30.00 to $33.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. JPMorgan Chase & Co. increased their target price on shares of Syndax Pharmaceuticals from $33.00 to $38.00 and gave the stock an “overweight” rating in a research note on Thursday, November 21st. Bank of America boosted their price target on Syndax Pharmaceuticals from $30.00 to $31.00 and gave the company a “buy” rating in a research report on Thursday, August 15th. Finally, Citigroup lifted their target price on Syndax Pharmaceuticals from $37.00 to $45.00 and gave the company a “buy” rating in a research note on Tuesday, November 19th. One analyst has rated the stock with a sell rating, one has given a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $37.64.

Syndax Pharmaceuticals Stock Down 0.1 %

Shares of NASDAQ SNDX opened at $16.70 on Tuesday. The stock’s 50 day moving average price is $18.41 and its two-hundred day moving average price is $19.76. Syndax Pharmaceuticals, Inc. has a 52-week low of $15.00 and a 52-week high of $25.34. The stock has a market capitalization of $1.43 billion, a P/E ratio of -4.60 and a beta of 0.92.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its earnings results on Tuesday, November 5th. The company reported ($0.98) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.13) by $0.15. The business had revenue of $12.50 million for the quarter, compared to analyst estimates of $9.16 million. During the same period last year, the company posted ($0.73) earnings per share. On average, analysts anticipate that Syndax Pharmaceuticals, Inc. will post -2.39 EPS for the current year.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).